$ALXN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ALEXION PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ALEXION PHARMACEUTICALS, INC.. Get notifications about new insider transactions in ALEXION PHARMACEUTICALS, INC. for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
May 24 2021 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 1,374 | 0 | 20,873 | 19.5 K to 20.9 K (+7.05 %) |
May 24 2021 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 1,962 | 0 | 19,499 | 17.5 K to 19.5 K (+11.19 %) |
Apr 01 2021 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Payment of Exercise | F | 154.03 | 2,332 | 359,198 | 349,166 | 351.5 K to 349.2 K (-0.66 %) |
Mar 02 2021 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | EVP, CFO | Grant | A | 0.00 | 24,473 | 0 | 63,940 | 39.5 K to 63.9 K (+62.01 %) |
Mar 02 2021 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 24,473 | 0 | 88,324 | 63.9 K to 88.3 K (+38.33 %) |
Mar 02 2021 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Grant | A | 0.00 | 7,616 | 0 | 38,499 | 30.9 K to 38.5 K (+24.66 %) |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Option Exercise | M | 140.16 | 11,000 | 1,541,760 | 0 | |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Option Exercise | M | 97.58 | 13,066 | 1,274,980 | 0 | |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Sell | S | 158.00 | 1,100 | 173,800 | 30,883 | 32 K to 30.9 K (-3.44 %) |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Sell | S | 157.76 | 13,066 | 2,061,292 | 31,983 | 45 K to 32 K (-29.00 %) |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Sell | S | 157.59 | 9,900 | 1,560,141 | 45,049 | 54.9 K to 45 K (-18.02 %) |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Buy | M | 140.16 | 11,000 | 1,541,760 | 54,949 | 43.9 K to 54.9 K (+25.03 %) |
Dec 21 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Buy | M | 97.58 | 13,066 | 1,274,980 | 43,949 | 30.9 K to 43.9 K (+42.31 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Payment of Exercise | F | 157.96 | 13,059 | 2,062,800 | 267,773 | 280.8 K to 267.8 K (-4.65 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Payment of Exercise | F | 157.96 | 72,533 | 11,457,313 | 280,832 | 353.4 K to 280.8 K (-20.53 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Grant | A | 0.00 | 162,707 | 0 | 353,365 | 190.7 K to 353.4 K (+85.34 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 157.96 | 1,725 | 272,481 | 30,883 | 32.6 K to 30.9 K (-5.29 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 157.96 | 7,087 | 1,119,463 | 32,608 | 39.7 K to 32.6 K (-17.85 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Grant | A | 0.00 | 15,371 | 0 | 39,695 | 24.3 K to 39.7 K (+63.19 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 157.96 | 3,261 | 515,108 | 67,301 | 70.6 K to 67.3 K (-4.62 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 157.96 | 18,134 | 2,864,447 | 70,562 | 88.7 K to 70.6 K (-20.45 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Grant | A | 0.00 | 40,677 | 0 | 88,696 | 48 K to 88.7 K (+84.71 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 157.96 | 2,913 | 460,137 | 46,345 | 49.3 K to 46.3 K (-5.91 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 157.96 | 16,925 | 2,673,473 | 49,258 | 66.2 K to 49.3 K (-25.57 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Grant | A | 0.00 | 37,965 | 0 | 66,183 | 28.2 K to 66.2 K (+134.54 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 93.53 | 40 | 3,741 | 63,851 | 63.8 K to 63.9 K (+0.06 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 157.96 | 3,261 | 515,108 | 63,811 | 67.1 K to 63.8 K (-4.86 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 157.96 | 18,134 | 2,864,447 | 67,072 | 85.2 K to 67.1 K (-21.28 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Grant | A | 0.00 | 40,677 | 0 | 85,206 | 44.5 K to 85.2 K (+91.35 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | EVP, CFO | Payment of Exercise | F | 157.96 | 2,510 | 396,480 | 39,467 | 42 K to 39.5 K (-5.98 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | EVP, CFO | Payment of Exercise | F | 157.96 | 6,853 | 1,082,500 | 41,977 | 48.8 K to 42 K (-14.03 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | EVP, CFO | Grant | A | 0.00 | 15,371 | 0 | 48,830 | 33.5 K to 48.8 K (+45.94 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Chiniara Ellen | EVP & Chief Legal O ... | Grant | A | 95.53 | 56 | 5,350 | 43,060 | 43 K to 43.1 K (+0.13 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Chiniara Ellen | EVP & Chief Legal O ... | Payment of Exercise | F | 157.96 | 2,988 | 471,984 | 43,004 | 46 K to 43 K (-6.50 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Chiniara Ellen | EVP & Chief Legal O ... | Payment of Exercise | F | 157.96 | 16,925 | 2,673,473 | 45,992 | 62.9 K to 46 K (-26.90 %) |
Dec 18 2020 | ALXN | ALEXION PHARMACEUT ... | Chiniara Ellen | EVP & Chief Legal O ... | Grant | A | 0.00 | 37,965 | 0 | 62,917 | 25 K to 62.9 K (+152.15 %) |
Dec 04 2020 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Sell | S | 122.26 | 1,530 | 187,058 | 16,102 | 17.6 K to 16.1 K (-8.68 %) |
Dec 04 2020 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Sell | S | 122.26 | 1,530 | 187,058 | 16,102 | 17.6 K to 16.1 K (-8.68 %) |
Dec 04 2020 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Payment of Exercise | F | 121.76 | 665 | 80,970 | 17,632 | 18.3 K to 17.6 K (-3.63 %) |
Dec 04 2020 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Payment of Exercise | F | 121.76 | 665 | 80,970 | 17,632 | 18.3 K to 17.6 K (-3.63 %) |
Dec 01 2020 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | EVP, CFO | Payment of Exercise | F | 124.00 | 1,298 | 160,952 | 33,459 | 34.8 K to 33.5 K (-3.73 %) |
Jul 28 2020 | ALXN | ALEXION PHARMACEUT ... | ALEXION PHARMACEUTICALS, INC. | 10% Owner | Option Exercise | C | 0.00 | 8,294,360 | 0 | 0 | |
Jul 28 2020 | ALXN | ALEXION PHARMACEUT ... | ALEXION PHARMACEUTICALS, INC. | 10% Owner | Buy | C | 0.00 | 1,109,910 | 0 | 1,109,910 | 0 to 1.1 M |
Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 115.00 | 1,433 | 164,795 | 28,218 | 29.7 K to 28.2 K (-4.83 %) |
Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 114.61 | 5,420 | 621,186 | 29,651 | 35.1 K to 29.7 K (-15.45 %) |
Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 114.61 | 1,403 | 160,798 | 35,071 | 36.5 K to 35.1 K (-3.85 %) |
Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP, Chief Experien ... | Payment of Exercise | F | 114.61 | 2,561 | 293,516 | 41,423 | 44 K to 41.4 K (-5.82 %) |
Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 114.61 | 2,784 | 319,074 | 44,529 | 47.3 K to 44.5 K (-5.88 %) |
Jun 09 2020 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 114.61 | 1,642 | 188,190 | 48,019 | 49.7 K to 48 K (-3.31 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,189 | 0 | 7,846,213 | 7.8 M to 7.8 M (+0.02 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 1,189 | 0 | 998,953 | 997.8 K to 999 K (+0.12 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 3,468 | 0 | 7,845,024 | 7.8 M to 7.8 M (+0.04 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Grant | A | 0.00 | 3,468 | 0 | 997,764 | 994.3 K to 997.8 K (+0.35 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 2,428 | 0 | 17,537 | 15.1 K to 17.5 K (+16.07 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Brennan David R | Director | Grant | A | 0.00 | 3,468 | 0 | 15,109 | 11.6 K to 15.1 K (+29.79 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 3,468 | 0 | 25,614 | 22.1 K to 25.6 K (+15.66 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Grant | A | 0.00 | 3,468 | 0 | 12,701 | 9.2 K to 12.7 K (+37.56 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Reinsdorf Judith A | Director | Grant | A | 0.00 | 595 | 0 | 11,515 | 10.9 K to 11.5 K (+5.45 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Reinsdorf Judith A | Director | Grant | A | 0.00 | 3,468 | 0 | 10,920 | 7.5 K to 10.9 K (+46.54 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 2,774 | 0 | 39,656 | 36.9 K to 39.7 K (+7.52 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 3,468 | 0 | 36,882 | 33.4 K to 36.9 K (+10.38 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Nader Francois | Director | Grant | A | 0.00 | 941 | 0 | 11,286 | 10.3 K to 11.3 K (+9.10 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Nader Francois | Director | Grant | A | 0.00 | 3,468 | 0 | 10,345 | 6.9 K to 10.3 K (+50.43 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | FRIEDMAN PAUL A | Director | Grant | A | 0.00 | 3,468 | 0 | 10,345 | 6.9 K to 10.3 K (+50.43 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Dunsire Deborah | Director | Grant | A | 0.00 | 941 | 0 | 12,134 | 11.2 K to 12.1 K (+8.41 %) |
May 18 2020 | ALXN | ALEXION PHARMACEUT ... | Dunsire Deborah | Director | Grant | A | 0.00 | 3,468 | 0 | 11,193 | 7.7 K to 11.2 K (+44.89 %) |
Mar 31 2020 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Payment of Exercise | F | 85.43 | 3,202 | 273,547 | 190,658 | 193.9 K to 190.7 K (-1.65 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 83.14 | 14,731 | 1,224,797 | 7,841,556 | 7.8 M to 7.8 M (+0.19 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 83.14 | 1,331 | 110,665 | 994,296 | 993 K to 994.3 K (+0.13 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.92 | 1,321 | 109,537 | 7,826,825 | 7.8 M to 7.8 M (+0.02 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.92 | 119 | 9,867 | 992,965 | 992.8 K to 993 K (+0.01 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.13 | 15,928 | 1,308,149 | 7,825,504 | 7.8 M to 7.8 M (+0.20 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 82.13 | 1,439 | 118,183 | 992,846 | 991.4 K to 992.8 K (+0.15 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.79 | 25,640 | 2,097,003 | 7,809,576 | 7.8 M to 7.8 M (+0.33 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.79 | 2,314 | 189,254 | 991,407 | 989.1 K to 991.4 K (+0.23 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.47 | 4,203 | 342,438 | 7,783,936 | 7.8 M to 7.8 M (+0.05 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.47 | 380 | 30,960 | 989,093 | 988.7 K to 989.1 K (+0.04 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.09 | 12,815 | 1,039,177 | 7,779,733 | 7.8 M to 7.8 M (+0.16 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 81.09 | 1,158 | 93,903 | 988,713 | 987.6 K to 988.7 K (+0.12 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 80.91 | 3,298 | 266,845 | 7,766,918 | 7.8 M to 7.8 M (+0.04 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 80.91 | 298 | 24,112 | 987,555 | 987.3 K to 987.6 K (+0.03 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.87 | 10,285 | 821,429 | 7,763,620 | 7.8 M to 7.8 M (+0.13 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.87 | 929 | 74,196 | 987,257 | 986.3 K to 987.3 K (+0.09 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.72 | 26,022 | 2,074,362 | 7,753,335 | 7.7 M to 7.8 M (+0.34 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.72 | 2,351 | 187,412 | 986,328 | 984 K to 986.3 K (+0.24 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.29 | 2,888 | 228,980 | 7,727,313 | 7.7 M to 7.7 M (+0.04 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.29 | 261 | 20,694 | 983,977 | 983.7 K to 984 K (+0.03 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.16 | 4,191 | 331,760 | 7,724,425 | 7.7 M to 7.7 M (+0.05 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.16 | 379 | 30,002 | 983,716 | 983.3 K to 983.7 K (+0.04 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 78.66 | 565 | 44,443 | 7,720,234 | 7.7 M to 7.7 M (+0.01 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 78.66 | 51 | 4,012 | 983,337 | 983.3 K to 983.3 K (+0.01 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.67 | 65,505 | 5,022,445 | 7,719,669 | 7.7 M to 7.7 M (+0.86 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.67 | 5,917 | 453,672 | 983,286 | 977.4 K to 983.3 K (+0.61 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.10 | 27,866 | 2,120,480 | 7,654,164 | 7.6 M to 7.7 M (+0.37 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 76.10 | 2,517 | 191,533 | 977,369 | 974.9 K to 977.4 K (+0.26 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.77 | 62,129 | 4,955,720 | 7,626,298 | 7.6 M to 7.6 M (+0.82 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.77 | 5,612 | 447,641 | 974,852 | 969.2 K to 974.9 K (+0.58 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.14 | 133,042 | 10,529,170 | 7,564,169 | 7.4 M to 7.6 M (+1.79 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 79.14 | 12,017 | 951,046 | 969,240 | 957.2 K to 969.2 K (+1.26 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.94 | 7,612 | 593,260 | 7,431,127 | 7.4 M to 7.4 M (+0.10 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.94 | 688 | 53,621 | 957,223 | 956.5 K to 957.2 K (+0.07 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.89 | 8,309 | 647,203 | 7,423,515 | 7.4 M to 7.4 M (+0.11 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 77.89 | 750 | 58,419 | 956,535 | 955.8 K to 956.5 K (+0.08 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 75.66 | 32,228 | 2,438,422 | 7,415,206 | 7.4 M to 7.4 M (+0.44 %) |
Mar 18 2020 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Buy | P | 75.66 | 2,911 | 220,251 | 955,785 | 952.9 K to 955.8 K (+0.31 %) |
Mar 02 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 92.97 | 216 | 20,082 | 21,283 | 21.5 K to 21.3 K (-1.00 %) |
Feb 10 2020 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 102.97 | 1,594 | 164,134 | 40,182 | 41.8 K to 40.2 K (-3.82 %) |
Feb 10 2020 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 102.97 | 1,406 | 144,776 | 28,221 | 29.6 K to 28.2 K (-4.75 %) |
Feb 10 2020 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 102.97 | 851 | 87,627 | 21,499 | 22.4 K to 21.5 K (-3.81 %) |
Dec 04 2019 | ALXN | ALEXION PHARMACEUT ... | Bazarko Daniel | SVP, Controller, CA ... | Payment of Exercise | F | 113.20 | 1,185 | 134,142 | 22,350 | 23.5 K to 22.4 K (-5.04 %) |
Dec 04 2019 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | EVP, CFO | Payment of Exercise | F | 113.20 | 5,441 | 615,921 | 24,760 | 30.2 K to 24.8 K (-18.02 %) |
Dec 02 2019 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Grant | A | 0.00 | 8,777 | 0 | 8,777 | 0 to 8.8 K |
Dec 02 2019 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Grant | A | 0.00 | 8,777 | 0 | 8,777 | 0 to 8.8 K |
Dec 02 2019 | ALXN | ALEXION PHARMACEUT ... | Carino Tanisha | EVP & CCAO | Grant | A | 0.00 | 8,777 | 0 | 8,777 | 0 to 8.8 K |
Jul 15 2019 | ALXN | ALEXION PHARMACEUT ... | Clancy Paul J | EVP, Chief Financia ... | Payment of Exercise | F | 124.20 | 5,230 | 649,566 | 90,447 | 95.7 K to 90.4 K (-5.47 %) |
Jul 02 2019 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 132.78 | 4,500 | 597,510 | 29,627 | 34.1 K to 29.6 K (-13.19 %) |
Jul 02 2019 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Sell | S | 132.78 | 4,500 | 597,510 | 29,627 | 34.1 K to 29.6 K (-13.19 %) |
Jun 24 2019 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | Chief Strategy & Bu ... | Sell | S | 132.00 | 578 | 76,296 | 30,201 | 30.8 K to 30.2 K (-1.88 %) |
Jun 11 2019 | ALXN | ALEXION PHARMACEUT ... | ORLOFF JOHN J | EVP, Research & Dev ... | Payment of Exercise | F | 118.61 | 2,786 | 330,447 | 37,791 | 40.6 K to 37.8 K (-6.87 %) |
Jun 11 2019 | ALXN | ALEXION PHARMACEUT ... | Goff Brian | EVP & Chief Commerc ... | Payment of Exercise | F | 118.61 | 1,643 | 194,876 | 41,776 | 43.4 K to 41.8 K (-3.78 %) |
Jun 11 2019 | ALXN | ALEXION PHARMACEUT ... | LAW ANNE-MARIE | EVP, Chief Experien ... | Payment of Exercise | F | 118.61 | 2,563 | 303,997 | 35,092 | 37.7 K to 35.1 K (-6.81 %) |
Jun 11 2019 | ALXN | ALEXION PHARMACEUT ... | Franchini Indrani Lall | EVP, Chief Complian ... | Payment of Exercise | F | 118.61 | 1,404 | 166,528 | 34,127 | 35.5 K to 34.1 K (-3.95 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.77 | 22,720 | 2,743,928 | 7,382,978 | 7.4 M to 7.4 M (-0.31 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.77 | 2,729 | 329,585 | 952,874 | 955.6 K to 952.9 K (-0.29 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.31 | 13,213 | 1,616,054 | 7,405,698 | 7.4 M to 7.4 M (-0.18 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.31 | 1,587 | 194,103 | 955,603 | 957.2 K to 955.6 K (-0.17 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.12 | 15,355 | 1,844,459 | 7,418,911 | 7.4 M to 7.4 M (-0.21 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 120.12 | 1,845 | 221,623 | 957,190 | 959 K to 957.2 K (-0.19 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.37 | 35,796 | 4,380,432 | 7,434,266 | 7.5 M to 7.4 M (-0.48 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 122.37 | 4,300 | 526,200 | 959,035 | 963.3 K to 959 K (-0.45 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 123.06 | 30,766 | 3,786,036 | 7,470,062 | 7.5 M to 7.5 M (-0.41 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 123.06 | 3,696 | 454,826 | 963,335 | 967 K to 963.3 K (-0.38 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 121.37 | 39,732 | 4,822,189 | 7,500,828 | 7.5 M to 7.5 M (-0.53 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 121.37 | 4,772 | 579,168 | 967,031 | 971.8 K to 967 K (-0.49 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 127.06 | 71,819 | 9,125,258 | 7,540,560 | 7.6 M to 7.5 M (-0.94 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 127.06 | 8,627 | 1,096,139 | 971,803 | 980.4 K to 971.8 K (-0.88 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 125.05 | 22,886 | 2,861,901 | 7,612,379 | 7.6 M to 7.6 M (-0.30 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 125.05 | 2,749 | 343,763 | 980,430 | 983.2 K to 980.4 K (-0.28 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 126.25 | 15,541 | 1,962,085 | 7,635,265 | 7.7 M to 7.6 M (-0.20 %) |
May 30 2019 | ALXN | ALEXION PHARMACEUT ... | BAKER BROS. ADVISORS LP | Director | Sell | S | 126.25 | 1,867 | 235,713 | 983,179 | 985 K to 983.2 K (-0.19 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | Mollen John T | Director | Grant | A | 0.00 | 2,726 | 0 | 9,233 | 6.5 K to 9.2 K (+41.89 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | Dunsire Deborah | Director | Grant | A | 0.00 | 740 | 0 | 7,725 | 7 K to 7.7 K (+10.59 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | Dunsire Deborah | Director | Grant | A | 0.00 | 2,726 | 0 | 6,985 | 4.3 K to 7 K (+64.01 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 2,181 | 0 | 33,414 | 31.2 K to 33.4 K (+6.98 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | COUGHLIN CHRISTOPHER J | Director | Grant | A | 0.00 | 2,726 | 0 | 31,233 | 28.5 K to 31.2 K (+9.56 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | Rummelt Andreas | Director | Grant | A | 0.00 | 2,726 | 0 | 22,146 | 19.4 K to 22.1 K (+14.04 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | Reinsdorf Judith A | Director | Grant | A | 0.00 | 467 | 0 | 7,452 | 7 K to 7.5 K (+6.69 %) |
May 17 2019 | ALXN | ALEXION PHARMACEUT ... | Reinsdorf Judith A | Director | Grant | A | 0.00 | 2,726 | 0 | 6,985 | 4.3 K to 7 K (+64.01 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | HANTSON LUDWIG | CEO | Grant | A | 0.00 | 37,198 | 0 | 170,836 | 133.6 K to 170.8 K (+27.83 %) |
Mar 05 2019 | ALXN | ALEXION PHARMACEUT ... | SARIN ARADHANA | Chief Strategy & Bu ... | Grant | A | 0.00 | 8,250 | 0 | 30,779 | 22.5 K to 30.8 K (+36.62 %) |